Pharmacokinetics and biodistribution of lonidamine/paclitaxel loaded, EGFR-targeted nanoparticles in an orthotopic animal model of multi-drug resistant breast cancer

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 7, Issue 4, 2011, Pages 435-444

  Milane, Lara ^a   Duan, Zhen feng ^b   Amiji, Mansoor ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Lonidamine; Multidrug resistant cancer; Nanoparticles; Paclitaxel; Pharmacokinetics

Indexed keywords

ANIMAL MODEL; ANTICANCER DRUG; BIODISTRIBUTIONS; BREAST CANCER; CAPROLACTONE; COMBINATION THERAPY; DRUG SOLUTIONS; EPIDERMAL GROWTH FACTOR RECEPTORS; ISOCRATIC; LONIDAMINE; MICE PLASMA; MULTIDRUG-RESISTANT CANCER; NANOCARRIERS; NON-TARGETED; ORTHOTOPIC; PACLITAXEL; PHARMACOKINETIC PROFILES; POLY(D ,L-LACTIDE-CO- GLYCOLIDE); TARGET SITES; TARGETED NANOPARTICLE; TISSUE DISTRIBUTIONS; TUMOR ACCUMULATION; TUMOR MASS;

CARBOXYLIC ACIDS; DISEASES; DRUG THERAPY; ETHYLENE; GLYCOLS; HIGH PRESSURE LIQUID CHROMATOGRAPHY; MAMMALS; ORGANIC POLYMERS; PEPTIDES; PHARMACOKINETICS; POLYETHYLENE GLYCOLS; TUMORS;

NANOPARTICLES;

EPIDERMAL GROWTH FACTOR RECEPTOR; LONIDAMINE; NANOCARRIER; PACLITAXEL; POLY[(DEXTRO LEVO LACTIDE CO GLYCOLIDE)POLY(ETHYLENE GLYCOL)]; POLYCAPROLACTONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG SOLUTION; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; KIDNEY; LIVER; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; SINGLE DRUG DOSE; TARGET ORGAN;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; INDAZOLES; MICE; MICE, NUDE; NANOPARTICLES; NANOTECHNOLOGY; PACLITAXEL; RECEPTOR, EPIDERMAL GROWTH FACTOR;

ANIMALIA; MUS;

EID: 79960704268     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2010.12.009     Document Type: Article

References (21)

1. Harris A.L., Hochhauser D. Mechanisms of multidrug resistance in cancer treatment. Acta Oncol 1992, 31:205-213.
2. Jamroziak K., Robak T. Pharmacogenomics of MDR1/ABCB1 gene: the influence on risk and clinical outcome of haematological malignancies. Hematology 2004, 9:91-105.
3. Leighton J.C., Goldstein L.J. P-glycoprotein in adult solid tumors. Expression and prognostic significance. Hematol Oncol Clin North Am 1995, 9:251-273.
4. Tredan O., Galmarini C.M., Patel K., Tannock I.F. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007, 99:1441-1454.
5. Tsuruo T., Naito M., Tomida A., Fujita N., Mashima T., Sakamoto H., et al. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci 2003, 94:15-21.
6. Yague E., Arance A., Kubitza L., O'Hare M., Jat P., Ogilvie C.M., et al. Ability to acquire drug resistance arises early during the tumorigenesis process. Cancer Res 2007, 67:1130-1137.
7. Rojo F., Albanell J., Rovira A., Corominas J.M., Manzarbeitia F. Targeted therapies in breast cancer. Semin Diagn Pathol 2008, 25:245-261.
8. Hsieh M.Y., Yang S., Raymond-Stinz M.A., Steinberg S., Vlachos D.G., Shu W., et al. Stochastic simulations of ErbB homo and heterodimerisation: potential impacts of receptor conformational state and spatial segregation. IET Syst Biol 2008, 2:256-272.
9. Kingsley J.D., Dou H., Morehead J., Rabinow B., Gendelman H.E., Destache C.J. Nanotechnology: a focus on nanoparticles as a drug delivery system. J Neuroimmune Pharmacol 2006, 1:340-350.
10. Batrakova E.V., Kabanov A.V. Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J Control Release 2008, 130:98-106.
11. Moghimi S.M., Hunter A.C., Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol Rev 2001, 53:283-318.
12. Sinha R., Kim G.J., Nie S., Shin D.M. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther 2006, 5:1909-1917.
13. Jabr-Milane L.S., van Vlerken L.E., Yadav S., Amiji M.M. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat Rev 2008, 34:592-602.
14. Milane L.J., Duan Z., Amiji M.M. Development of EGFR-targeted polymer blend nanocarriers for paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells. Mol Pharm 2010, epub ahead of print. 10.1021/mp1002653.
15. Li Z., Zhao R., Wu X., Sun Y., Yao M., Li J., et al. Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics. FASEB J 2005, 19:1978-1985.
16. Song S., Liu D., Peng J., Sun Y., Li Z., Gu J.R., et al. Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo. Int J Pharm 2008, 363:155-161.
17. Chawla J.S., Amiji M.M. Biodegradable poly(e{open}-caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen. Int J Pharm 2002, 249:127-138.
18. Shenoy D.B., Amiji M.M. Poly(ethylene oxide)-modified poly(e{open}-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. Int J Pharm 2005, 293:261-270.
19. Grippa E., Gatto M.T., Leone M.G., Tita B., Adbel-Haq H., Vitalone A., et al. Analysis of lonidamine in rat serum and testis by high performance liquid chromatography. Biomed Chromatogr 2001, 15:1-8.
20. Ganta S., Amiji M. Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm 2009, 6:928-939.
21. Zhang Y., Huo M., Zhou J., Xie S. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed 2010, 99:306-314.